Ligand Pharmaceuticals (LGND) Interest Coverage Ratio Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.17% |
| Dec 31, 2025 | 16.71% |
| Sep 30, 2025 | 151.69% |
| Jun 30, 2025 | 44.99% |
| Mar 31, 2025 | -149.28% |
| Dec 31, 2024 | -56.78% |
| Sep 30, 2024 | 56.52% |
| Jun 30, 2024 | -101.07% |
| Mar 31, 2024 | -25.58% |
| Dec 31, 2023 | -77.41% |
| Sep 30, 2023 | 330.32% |
| Jun 30, 2023 | -27.27% |
| Mar 31, 2023 | 40.94% |
| Dec 31, 2022 | -64.75% |
| Sep 30, 2022 | 50.15% |
| Jun 30, 2022 | 38.39% |
| Mar 31, 2022 | -4.89% |
| Dec 31, 2021 | 9.86% |
| Sep 30, 2021 | 15.06% |
| Jun 30, 2021 | 48.41% |
| Mar 31, 2021 | -30.60% |
| Sep 30, 2020 | -27.26% |
| Jun 30, 2020 | -4.91% |
| Mar 31, 2020 | -17.02% |
| Sep 30, 2019 | -17.57% |
| Jun 30, 2019 | -15.56% |
| Mar 31, 2019 | 35.17% |
| Sep 30, 2018 | -23.17% |
| Jun 30, 2018 | 9.31% |
| Mar 31, 2018 | 19.81% |
| Sep 30, 2017 | 35.17% |
| Jun 30, 2017 | 29.45% |
| Mar 31, 2017 | 37.43% |
| Dec 31, 2016 | -3.34% |
| Sep 30, 2016 | 18.91% |
| Jun 30, 2016 | 25.25% |
| Mar 31, 2016 | 27.98% |
| Sep 30, 2015 | 14.89% |
| Jun 30, 2015 | 14.93% |